Teijin Pharma Limited.
https://www.teijin-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Teijin Pharma Limited.
Chiesi Takes Long View To Build Japan Rare Disease Presence
After expanding its local portfolio through acquisitions and partnerships, Chiesi is now aiming to build its presence in Japan's rare disease sector over the long term, helped by development of global products and possible new alliances.
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Gedeon Richter’s Q1 Hit By Weak Ruble But Expects More M&A In Q2
With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Rehabilitation Equipment and Devices
- Other Names / Subsidiaries
-
- MedTech Heart
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice